Indivior Pharmaceuticals (INDV) Receivables - Net (2021 - 2026)
Indivior Pharmaceuticals has reported Receivables - Net over the past 6 years, most recently at $273.0 million for Q1 2026.
- For Q1 2026, Receivables - Net rose 12.35% year-over-year to $273.0 million; the TTM value through Mar 2026 reached $273.0 million, up 12.35%, while the annual FY2025 figure was $253.0 million, 0.39% changed from the prior year.
- Receivables - Net for Q1 2026 was $273.0 million at Indivior Pharmaceuticals, up from $253.0 million in the prior quarter.
- Over five years, Receivables - Net peaked at $273.0 million in Q1 2026 and troughed at $220.0 million in Q4 2022.
- A 5-year average of $248.4 million and a median of $251.0 million in 2024 define the central range for Receivables - Net.
- Biggest five-year swings in Receivables - Net: increased 15.45% in 2023 and later decreased 7.34% in 2025.
- Year by year, Receivables - Net stood at $220.0 million in 2022, then increased by 15.45% to $254.0 million in 2023, then changed by 0.0% to $254.0 million in 2024, then fell by 0.39% to $253.0 million in 2025, then rose by 7.91% to $273.0 million in 2026.
- Business Quant data shows Receivables - Net for INDV at $273.0 million in Q1 2026, $253.0 million in Q4 2025, and $259.0 million in Q3 2025.